SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
4.420
+0.010 (0.23%)
At close: Jan 29, 2026, 4:00 PM EST
4.420
0.00 (0.00%)
After-hours: Jan 29, 2026, 4:00 PM EST
SAB Biotherapeutics Revenue
SAB Biotherapeutics had revenue of $114.70K in the twelve months ending September 30, 2025, down -92.42% year-over-year. In the year 2024, SAB Biotherapeutics had annual revenue of $1.32M, down -40.94%.
Revenue (ttm)
$114.70K
Revenue Growth
-92.42%
P/S Ratio
1,834.62
Revenue / Employee
$1,821
Employees
63
Market Cap
209.47M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.32M | -916.58K | -40.94% |
| Dec 31, 2023 | 2.24M | -21.67M | -90.63% |
| Dec 31, 2022 | 23.90M | -36.97M | -60.73% |
| Dec 31, 2021 | 60.88M | 5.64M | 10.21% |
| Dec 31, 2020 | 55.24M | 51.80M | 1,504.91% |
| Dec 31, 2019 | 3.44M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Century Therapeutics | 113.34M |
| Arcturus Therapeutics Holdings | 97.60M |
| Alector | 69.05M |
| Editas Medicine | 46.38M |
| Ovid Therapeutics | 6.61M |
| Camp4 Therapeutics | 3.80M |
| Inhibikase Therapeutics | 1.00 |
SABS News
- 22 days ago - SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director - GlobeNewsWire
- 23 days ago - SAB BIO to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 6 weeks ago - First Patient Dosed in SAB BIO's SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1D - GlobeNewsWire
- 6 weeks ago - SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D - GlobeNewsWire
- 7 weeks ago - SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes Management - GlobeNewsWire
- 2 months ago - SAB BIO Reports Third Quarter Financial Results and Recent Business Highlights - GlobeNewsWire
- 3 months ago - SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142 - GlobeNewsWire
- 3 months ago - SAB BIO to Participate in Upcoming Investor Conferences - GlobeNewsWire